Institute of Human Nutrition and Dietetics, Poznan University of Life Sciences, Wojska Polskiego St. 31, 60-624 Poznań, Poland.
Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Szamarzewskiego St. 82/84, 60-569 Poznań, Poland.
Nutrients. 2018 Sep 11;10(9):1284. doi: 10.3390/nu10091284.
Antihypertensive drugs affect mineral metabolism, inflammation, and the oxidative state. The aim of this study was to evaluate the effects of antihypertensive monopharmacotherapy with diuretics, β-blockers, calcium antagonists (Ca-antagonists), angiotensin-converting enzyme inhibitors (ACE-I), and angiotensin II receptor antagonists (ARBs) on zinc (Zn), iron (Fe), and copper (Cu) status, parameters of oxidative and inflammatory states, and glucose and lipid metabolism in patients with newly diagnosed primary arterial hypertension (AH).
Ninety-eight hypertensive subjects received diuretics, β-blockers, Ca-antagonists, ACE-I, or ARB for three months. Zn, Fe, and Cu concentrations were determined in blood, urine, and hair.
A decrease in zinc serum and erythrocyte concentration and an increase in zinc urine concentration were registered after diuretic administration. Ca-antagonists led to a decrease in erythrocyte zinc concentration. A decrease in serum zinc concentration was observed after ACE-I. A decrease in triglyceride serum concentration was noted after ACE-I therapy, and a decrease in tumor necrosis factor-α serum concentration was seen following administration of Ca-antagonists. Hypotensive drugs led to decreases in catalase and superoxide dismutase serum concentrations.
Three-months of monotherapy with diuretics, Ca-antagonists, or ACE-I impairs zinc status in patients with newly diagnosed primary AH. Antihypertensive monopharmacotherapy and zinc metabolism alterations affect lipid metabolism, the oxidative state, and the inflammatory state.
降压药物会影响矿物质代谢、炎症和氧化状态。本研究旨在评估利尿剂、β受体阻滞剂、钙通道阻滞剂（Ca 拮抗剂）、血管紧张素转换酶抑制剂（ACEI）和血管紧张素 II 受体拮抗剂（ARB）单一抗高血压治疗对新诊断原发性高血压（AH）患者锌（Zn）、铁（Fe）和铜（Cu）状态、氧化和炎症状态参数以及葡萄糖和脂质代谢的影响。
98 例高血压患者接受利尿剂、β受体阻滞剂、Ca 拮抗剂、ACEI 或 ARB 治疗三个月。在血液、尿液和头发中测定 Zn、Fe 和 Cu 浓度。
利尿剂治疗后血清和红细胞锌浓度降低，尿锌浓度升高。Ca 拮抗剂导致红细胞锌浓度降低。ACEI 后血清锌浓度降低。ACEI 治疗后血清甘油三酯浓度降低，Ca 拮抗剂治疗后肿瘤坏死因子-α血清浓度降低。降压药物导致血清过氧化氢酶和超氧化物歧化酶浓度降低。
新诊断原发性 AH 患者接受利尿剂、Ca 拮抗剂或 ACEI 单药治疗三个月会损害锌状态。抗高血压单药治疗和锌代谢改变会影响脂质代谢、氧化状态和炎症状态。
